Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
November/December 2010, Vol 1, No 6
November/December 2010, Vol 1, No 6
CER and Personalized Medicine Face Hurdles
By
Colin Gittens
ECRI Personalized Medicine Conference
November/December 2010, Vol 1, No 6
Bethesda, MD—Implementing and effectively using comparative effectiveness research (CER) and personalized medicine (PM) will require time and better communication among the research community conducting these types of studies and with the public that will be impacted by them, according to participants in a panel discussion on the societal implications of CER and PM held during the ECRI Institute’s Comparative Ef fectiveness and Personalized Medicine: An Essential Interface conference.
Read Article
Determining Coverage for CER and Personalized Medicine
By
Colin Gittens
ECRI Personalized Medicine Conference
November/December 2010, Vol 1, No 6
Bethesda, MD—Greater adoption of personalized medicine and comparative effectiveness research (CER) in healthcare will depend on coverage of these approaches by public and private payers. But payer evaluation of these approaches is hampered by legislative roadblocks and a lack of research in CER and slowness in adopting CER into clinical practice, according to speakers at a session of the ECRI Institute’s Comparative Effectiveness and Personalized Medicine: An Essential Interface conference.
Read Article
Benefit to Longer Chemotherapy in Metastatic Breast Cancer
By
Charles Bankhead
ESMO 2010 Conference
,
ESMO
November/December 2010, Vol 1, No 6
Milan—Continuing first-line chemotherapy for metastatic breast cancer until disease progression significantly improves overall (OS) and progression free survival (PFS), according to a meta-analysis reported at the 35th ESMO Congress.
Read Article
High Cost to Managing Colorectal Cancer Toxicities
By
Caroline Helwick
ESMO 2010 Conference
,
ESMO
November/December 2010, Vol 1, No 6
Milan—Because the toxicity profiles for the 3 monoclonal antibodies used in treating metastatic colorectal cancer (mCRC) differ, there are substantial differences in the cost of treating side effects, according to research presented at the 35th ESMO Congress.
Read Article
Streamlining Cancer Care in Michigan
By
Colin Gittens
Practice Management
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
Setting up a statewide cancer pathway program requires sophisticated data collection and analytic capability, as well as a collaborative mindset among participants, according to
Kurt Neumann, MD
, Medical Director of Managed Care and Quality Initiatives for the International Oncology Network, a division of Amerisource Bergen Specialty Group.
Read Article
CMS Releases Outpatient Payment Rules for Physicians and Hospitals
By
Crystal Kuntz, MPA
Health Policy
,
Policies & Guidelines
November/December 2010, Vol 1, No 6
On November 2, 2010, the Centers for Medicare & Medicaid Services (CMS) issued its Physician Fee Schedule and Hospital Outpatient Prospective Payment System final rules for 2011.
Read Article
Continued Pressures on Community Cancer Centers
By
Colin Gittens
Practice Management
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
Consolidation and cost pressures remain key concerns for community cancer centers, according to
Christian Downs, MHA, JD
, the executive director of the Association of Community Cancer Centers (ACCC).
Read Article
Contralateral Prophylactic Mastectomy Improves Survival, Is Cost-Effective in Some
By
Caroline Helwick
ASCO Breast Cancer Symposium
November/December 2010, Vol 1, No 6
National Harbor, MD—Multiple benefitswere observed for contralateral prophylactic mastectomy (CPM), including cost-effectiveness, in studies presented at the 2010 ASCO Breast Cancer Symposium by investigators from the Mayo Clinic, Rochester, MN.
Read Article
Significant Impact for New Prostate Cancer Therapy
By
Charles Bankhead
ESMO 2010 Conference
,
ESMO
November/December 2010, Vol 1, No 6
Milan—Men with castration-resistant prostate cancer (CRPC) gained 4 months in overall survival (OS) when treated with the novel antiandrogen abiraterone acetate, data from a large randomized trial showed.
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma